#United States #New York #Levi & Korsinsky #Inc. #Securities Class Action #Ardelyx

Important Update for Ardelyx, Inc. Shareholders

Levi & Korsinsky, LLP is issuing a critical alert to investors in Ardelyx, Inc. (NASDAQ: ARDX) regarding the existence of a pending securities class action that could impact shareholders who have experienced losses. The class action period spans from January 13, 2025, to August 6, 2026. This alert serves as a notification and guidance for those who may be affected.

Background of the Case

Recent disclosures have revealed troubling information related to Ardelyx's patient-access strategies. On August 6, 2026, following the announcement regarding increased payer utilization management controls, Ardelyx shares plummeted approximately 18% in a single trading session. Investors were assured by management of the effectiveness of the company's patient-access strategies which were claimed to be functioning and contributing to company growth. However, it has been alleged that while these assurances were made, stricter prior authorization and step edit requirements were actually hindering new patient starts for their products, IBSRELA and XPHOZAH.

Allegations Against Ardelyx's Management

The lawsuit indicates that Ardelyx's management knowingly misled investors regarding the operational realities of their patient-access initiatives. Claiming that their patient access was well-managed, they did not disclose the restrictive prior authorization barriers that were growing at the same time. As part of their communication on February 20, 2025, management stated that prescriptions should be made as per patient need, promising that the company would handle access and affordability on its end. However, the lawsuit argues that these statements were misleading, neglecting to mention that red tape surrounding patient access was already a significant impediment at that time.

The Implications of Utilization Management Trends

Prior authorization, a necessity for obtaining approval prior to dispensing medications, has been tightened, with each extra requirement serving to delay or jeopardize a new patient start. Additionally, step edits, which necessitate a patient to fail other therapies before receiving non-first-line treatments, have become a common strategy among payers. Management had previously defended their approach, indicating a high approval rate for patient prescriptions through their ArdelyxAssist program but failed to note how much access restraint was truly in play.

The ramifications of these practices can be severe for a company dependent on new patient starts for their revenue. Per the lawsuit, many investors bought ARDX stock at prices inflated by incorrect assumptions about the company's patient-access strategies, only to realize significant losses as guidance for revenue related to IBSRELA and XPHOZAH was adjusted downward due to increased payer management processes.

Deadline for Lead Plaintiff Appointment

For shareholders wishing to participate in the class action lawsuit, there is an important deadline to note: applications for lead plaintiff appointment must be submitted by November 16, 2026. This period pertains specifically to those who want to take a more active role in the proceedings. Investors who choose not to apply can still engage in any future settlements without needing to act promptly.

Engaging with the Lawsuit

If you are an Ardelyx shareholder who acquired stock during the class period and suffered losses as a result of these matters, you are encouraged to gather relevant brokerage documentation detailing purchasing dates, the number of shares bought, and pricing. You can then reach out to Levi & Korsinsky for a complimentary evaluation of your potential recovery options.

Investors are reminded that taking part in such cases generally incurs no upfront costs on their end, and more often than not, they won’t need to make any appearances in court. Should there be a successful settlement, eligible parties will typically fill out a simple form to reclaim their share.

Contact Information

For additional information, interested parties can contact:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: (212) 363-7500
Email: [email protected]

In closing, this alert is essential for investors who need to stay informed about developments that could affect their financial interests in Ardelyx, Inc. Shareholder rights are vital, and acting within the specified timeframe is crucial for those wishing to pursue action.